Keros Therapeutics, Inc. (KROS)
- Previous Close
14.56 - Open
14.45 - Bid 13.72 x 200
- Ask 17.39 x 200
- Day's Range
13.50 - 14.45 - 52 Week Range
9.12 - 72.37 - Volume
1,042,064 - Avg. Volume
1,084,755 - Market Cap (intraday)
558.813M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-5.00 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.70
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
www.kerostx.comRecent News: KROS
View More
Performance Overview: KROS
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KROS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KROS
View MoreValuation Measures
Market Cap
558.81M
Enterprise Value
17.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
145.11
Price/Book (mrq)
0.98
Enterprise Value/Revenue
5.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.73%
Return on Equity (ttm)
-41.46%
Revenue (ttm)
3.55M
Net Income Avi to Common (ttm)
-187.35M
Diluted EPS (ttm)
-5.00
Balance Sheet and Cash Flow
Total Cash (mrq)
559.93M
Total Debt/Equity (mrq)
3.30%
Levered Free Cash Flow (ttm)
-108.31M